Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter phase I/II study of XNW28012 in advanced solid tumors
CTR20233056Phase 2Active
- Sponsor
- Sinovent
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of xnw28012 in Nonhematologic neoplasms, ovarian cancer, Cervical Cancer (CC), pancreatic cancer (PDAC), prostate cancer (PCa), sponsored by Sinovent. Started Dec 2023; status: active.
02
Drugs
xnw28012
03
Conditions
Nonhematologic neoplasmsovarian cancerCervical Cancer (CC)pancreatic cancer (PDAC)prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20233056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233056.